Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism mGluR2 antagonists(Metabotropic glutamate receptor 2 antagonists), mGluR3 antagonists(Metabotropic glutamate receptor 3 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization- |
Active Organization- |
Inactive Organization ![]() |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder, Major | Phase 1 | US | Gate Neurosciences, Inc.Startup | 11 Oct 2020 |
Disorders of Excessive Somnolence | Phase 1 | US | Gate Neurosciences, Inc.Startup | 09 Oct 2020 |